Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland.
Polish Mother's Memorial Hospital-Research Institute, Lodz, Poland.
Endocrine. 2017 Sep;57(3):474-480. doi: 10.1007/s12020-017-1366-6. Epub 2017 Aug 9.
Copeptin (pre-proAVP) secreted in equimolar amounts with vasopressin closely reflects vasopressin release. Copeptin has been shown to subtly mirror stress potentially mediated via corticotrophin-releasing hormone. To further test a potential direct interaction of corticotrophin-releasing hormone with copeptin release, which could augment vasopressin effects on pituitary function, we investigated copeptin response to corticotrophin-releasing hormone.
Cortisol, adrenocorticotropin and copeptin were measured in 18 healthy controls and 29 subjects with a history of pituitary disease during standard corticotrophin-releasing hormone test.
Patients with previous pituitary disease were subdivided in a group passing the test (P1, n = 20) and failing (P2, n = 9). The overall copeptin response was higher in controls than in subjects with pituitary disease (area under the curve, p = 0.04 for P1 + P2) with a maximum increase in controls from 3.84 ± 2.86 to 12.65 ± 24.87 pmol/L at 30 min, p < 0.05. In contrast, both groups of pituitary patients lacked a significant copeptin response to corticotrophin-releasing hormone, and even in P1, where adrenocorticotropin concentrations increased fourfold (mean, 21.48 vs. 91.53 pg/mL, p < 0.01), copeptin did not respond (e.g., 4.35 ± 5.81 vs. 5.36 ± 6.79 pmol/L, at 30 min, p = ns).
Corticotrophin-releasing hormone is able to stimulate copeptin release in healthy controls suggesting a direct interaction of corticotrophin-releasing hormone and vasopressin/vasopressin. Interestingly, this relation is altered already in the group of pituitary patients who pass the standard corticotrophin-releasing hormone test indicating (1) the corticotrophin-releasing hormone-adrenocorticotropin-cortisol response is largely independent from the vasopressin system, but (2) the corticotrophin-releasing hormone-vasopressin interaction reflected by copeptin may be much more sensitive to reveal subtle alterations in the regulation of pituitary function.
与血管加压素等量分泌的 copeptin(前 proAVP)紧密反映血管加压素的释放。已经表明,copeptin 微妙地反映了潜在的通过促肾上腺皮质激素释放激素介导的应激。为了进一步测试促肾上腺皮质激素释放激素与 copeptin 释放之间的潜在直接相互作用,这种相互作用可能增强血管加压素对垂体功能的影响,我们研究了 copeptin 对促肾上腺皮质激素释放激素的反应。
在标准促肾上腺皮质激素释放激素试验中,测量了 18 名健康对照者和 29 名既往有垂体疾病患者的皮质醇、促肾上腺皮质激素和 copeptin。
既往有垂体疾病的患者分为通过试验的一组(P1,n=20)和未通过的一组(P2,n=9)。与患有垂体疾病的患者相比,对照组的总体 copeptin 反应更高(曲线下面积,P1+P2 时为 p=0.04),对照组的最大增加值为 30 分钟时从 3.84±2.86 增加到 12.65±24.87 pmol/L,p<0.05。相比之下,两组垂体患者对促肾上腺皮质激素释放激素均缺乏明显的 copeptin 反应,甚至在 P1 中,促肾上腺皮质激素浓度增加了四倍(平均值,21.48 与 91.53 pg/mL,p<0.01),copeptin 也没有反应(例如,30 分钟时分别为 4.35±5.81 与 5.36±6.79 pmol/L,p=ns)。
促肾上腺皮质激素释放激素能够刺激健康对照者的 copeptin 释放,这表明促肾上腺皮质激素释放激素和血管加压素/血管加压素之间存在直接相互作用。有趣的是,这种关系在通过标准促肾上腺皮质激素释放激素试验的垂体患者组中已经发生改变,这表明(1)促肾上腺皮质激素释放激素-促肾上腺皮质激素-皮质醇反应在很大程度上独立于血管加压素系统,但(2)通过 copeptin 反映的促肾上腺皮质激素-血管加压素相互作用可能对揭示垂体功能调节的细微变化更为敏感。